{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:15:15Z","timestamp":1788207315222,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adherence to antihypertensive medication, alongside lifestyle modifications, is fundamental to managing hypertension and reducing the risk of cardiovascular disease. Attention-deficit\/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder associated with a range of cardiovascular diseases, including hypertension. ADHD medication has also been associated with hypertension. However, the influence of ADHD and ADHD medication on discontinuation and adherence to antihypertensive treatments is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multinational cohort study using electronic health databases from seven countries, which included adults who initiated antihypertensive medication between 2010 and 2020. ADHD was identified by a diagnosis of ADHD or dispensation of ADHD medications. The outcomes were (1) time to the first discontinuation of antihypertensive medication and (2) poor adherence, defined as the proportion of days covered (PDC) below 80% during 1-, 2-, and 5-year follow-up periods. We used Cox proportional hazards models and logistic regression to estimate associations, adjusting for age, sex, and calendar year of antihypertensive medication initiation. We pooled results from different countries via random-effects meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 12,174,321 adults who initiated antihypertensive medication during the study period, including 320,691 (2.6%) with ADHD. In the pooled analysis across all countries, ADHD was associated with an increased rate of discontinuation in 5-year follow-up of antihypertensive medication (hazard ratio [HR] 1.14; 95% CI, 1.02\u20131.27). In age-stratified analyses, ADHD was associated with a higher rate of antihypertensive medication discontinuation in middle-aged (HR, 1.11; 95% CI, 1.01\u20131.23) and older adults (HR, 1.14; 95% CI, 1.01\u20131.29), but not in young adults. Individuals with ADHD also had higher odds of poor adherence across 1 year after treatment initiation (odds ratio [OR] 1.45, 95% CI 1.26\u20131.67) to 5 years (OR 1.64, 95% CI 1.34\u20132.00). Among those with ADHD, use of ADHD medications was associated with lower odds of poor adherence (1 year OR 0.66, 95% CI 0.60\u20130.73; 5 years OR 0.58, 95% CI 0.46\u20130.72).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adults with ADHD are more likely to discontinue antihypertensive treatment and exhibit poor medication adherence. However, ADHD medication use appears to be associated with better adherence among individuals with ADHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04714-1","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:03:19Z","timestamp":1771585399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ADHD and adherence to antihypertensive medication treatment: a multinational cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Honghui","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm B.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Brikell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Wimberley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang-James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aske","family":"Astrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Dalsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Dige","family":"Semark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Engeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Faraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Klungs\u00f8yr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Snieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S. C.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"11","key":"4714_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802.","journal-title":"Nat Rev Cardiol"},{"key":"4714_CR2","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, C\u00edfkov\u00e1 R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"4714_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"issue":"6","key":"4714_CR4","first-page":"999","volume":"3","author":"M Veronesi","year":"2007","unstructured":"Veronesi M, Cicero AF, Prandin MG, Dormi A, Cosentino E, Strocchi E, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3(6):999\u20131005.","journal-title":"Vasc Health Risk Manag"},{"issue":"11","key":"4714_CR5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.amjhyper.2006.04.006","volume":"19","author":"M Burnier","year":"2006","unstructured":"Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy*. Am J Hypertens. 2006;19(11):1190\u20136.","journal-title":"Am J Hypertens"},{"issue":"1","key":"4714_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-024-00495-0","volume":"10","author":"SV Faraone","year":"2024","unstructured":"Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Primers. 2024;10(1):11.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4714_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/wps.21020","volume":"21","author":"L Li","year":"2022","unstructured":"Li L, Chang Z, Sun J, Garcia-Argibay M, Du Rietz E, Dobrosavljevic M, et al. Attention-deficit\/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort study. World Psychiatry. 2022;21(3):452\u20139.","journal-title":"World Psychiatry"},{"issue":"3","key":"4714_CR8","doi-asserted-by":"publisher","first-page":"e12158","DOI":"10.1002\/jcv2.12158","volume":"3","author":"L Li","year":"2023","unstructured":"Li L, Yao H, Zhang L, Garcia-Argibay M, Du Rietz E, Brikell I, et al. Attention-deficit\/hyperactivity disorder is associated with increased risk of cardiovascular diseases: a systematic review and meta-analysis. JCPP Adv. 2023;3(3):e12158.","journal-title":"JCPP Adv"},{"issue":"11","key":"4714_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/14779072.2023.2279608","volume":"21","author":"H Larsson","year":"2023","unstructured":"Larsson H. How can we improve the management of individuals with attention deficit hyperactivity disorders and co-occurring cardiometabolic disease? Expert Rev Cardiovasc Ther. 2023;21(11):725\u20138.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"4714_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12916-022-02314-3","volume":"20","author":"M Micha\u00eblsson","year":"2022","unstructured":"Micha\u00eblsson M, Yuan S, Melhus H, Baron JA, Byberg L, Larsson SC, et al. The impact and causal directions for the associations between diagnosis of ADHD, socioeconomic status, and intelligence by use of a bi-directional two-sample Mendelian randomization design. BMC Med. 2022;20(1):106.","journal-title":"BMC Med"},{"issue":"7","key":"4714_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1751-7176.2009.00138.x","volume":"11","author":"WJ Elliott","year":"2009","unstructured":"Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich). 2009;11(7):376\u201382.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"4714_CR12","first-page":"58","volume":"1","author":"AYL Chan","year":"2023","unstructured":"Chan AYL, Ma TT, Lau WCY, Ip P, Coghill D, Gao L, et al. Attention-deficit\/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal study. eClinicalMedicine. 2023;1:58.","journal-title":"eClinicalMedicine"},{"issue":"10","key":"4714_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","volume":"5","author":"SR Raman","year":"2018","unstructured":"Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824\u201335.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"4714_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"The Lancet Psychiatry"},{"issue":"9","key":"4714_CR15","first-page":"e45995","volume":"15","author":"A Nanda","year":"2023","unstructured":"Nanda A, Janga LSN, Sambe HG, Yasir M, Man RK, Gogikar A, et al. Adverse effects of stimulant interventions for attention deficit hyperactivity disorder (ADHD): a comprehensive systematic review. Cureus. 2023;15(9):e45995.","journal-title":"Cureus"},{"issue":"8","key":"4714_CR16","doi-asserted-by":"publisher","first-page":"e5887","DOI":"10.1002\/pds.5887","volume":"33","author":"H Zoega","year":"2024","unstructured":"Zoega H, Falster Michael O, Gillies Malcolm B, Litchfield M, Camacho X, Bruno C, et al. The medicines intelligence data platform: a population-based data resource from New South Wales, Australia. Pharmacoepidemiol Drug Saf. 2024;33(8):e5887.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4714_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/CLEP.S314959","volume":"13","author":"K Laugesen","year":"2021","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533\u201354.","journal-title":"Clin Epidemiol"},{"key":"4714_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-244X-12-219","volume":"12","author":"S McCarthy","year":"2012","unstructured":"McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry. 2012;12:219.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"4714_CR19","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035.","journal-title":"JAMIA Open"},{"issue":"7624","key":"4714_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"11","key":"4714_CR21","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00228-013-1555-z","volume":"69","author":"M Qvarnstr\u00f6m","year":"2013","unstructured":"Qvarnstr\u00f6m M, Kahan T, Kieler H, Brandt L, Hasselstr\u00f6m J, Bengtsson Bostr\u00f6m K, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69(11):1955\u201364.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4714_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/HYPERTENSIONAHA.118.12495","volume":"74","author":"GS Tajeu","year":"2019","unstructured":"Tajeu GS, Kent ST, Huang L, Bress AP, Cuffee Y, Halpern MT, et al. Antihypertensive medication nonpersistence and low adherence for adults <65 years initiating treatment in 2007\u20132014. Hypertension. 2019;74(1):35\u201346.","journal-title":"Hypertension"},{"issue":"1","key":"4714_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","volume":"14","author":"D Prieto-Merino","year":"2021","unstructured":"Prieto-Merino D, Mulick A, Armstrong C, Hoult H, Fawcett S, Eliasson L, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets. J Pharm Policy Pract. 2021;14(1):113.","journal-title":"J Pharm Policy Pract"},{"issue":"6","key":"4714_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/ajhp\/zxab392","volume":"79","author":"J Loucks","year":"2022","unstructured":"Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A. Proportion of days covered as a measure of medication adherence. Am J Health-Syst Pharm. 2022;79(6):492\u20136.","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"4714_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S2215-0366(23)00332-2","volume":"11","author":"I Brikell","year":"2024","unstructured":"Brikell I, Yao H, Li L, Astrup A, Gao L, Gillies MB, et al. ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases. Lancet Psychiatry. 2024;11(1):16\u201326.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"4714_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/jrsm.1490","volume":"12","author":"RCM van Aert","year":"2021","unstructured":"van Aert RCM, Schmid CH, Svensson D, Jackson D. Study specific prediction intervals for random-effects meta-analysis: a tutorial: prediction intervals in meta-analysis. Res Synth Methods. 2021;12(4):429\u201347.","journal-title":"Res Synth Methods"},{"issue":"6","key":"4714_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jhealeco.2006.03.001","volume":"25","author":"J Currie","year":"2006","unstructured":"Currie J, Stabile M. Child mental health and human capital accumulation: the case of ADHD. J Health Econ. 2006;25(6):1094\u2013118.","journal-title":"J Health Econ"},{"issue":"5","key":"4714_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1352\/1944-7558-125.5.389","volume":"125","author":"O Lindly","year":"2020","unstructured":"Lindly O, Crossman M, Eaves M, Philpotts L, Kuhlthau K. Health literacy and health outcomes among children with developmental disabilities: a systematic review. Am J Intellect Dev Disabil. 2020;125(5):389\u2013407.","journal-title":"Am J Intellect Dev Disabil"},{"key":"4714_CR29","doi-asserted-by":"publisher","first-page":"649399","DOI":"10.3389\/fpsyt.2021.649399","volume":"12","author":"S Young","year":"2021","unstructured":"Young S, Asherson P, Lloyd T, Absoud M, Arif M, Colley WA, et al. Failure of healthcare provision for attention-deficit\/hyperactivity disorder in the United Kingdom: a consensus statement. Front Psychiatry. 2021;12:649399.","journal-title":"Front Psychiatry"},{"issue":"11","key":"4714_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/jhh.2017.48","volume":"31","author":"DM van der Laan","year":"2017","unstructured":"van der Laan DM, Elders PJM, Boons CCLM, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors associated with antihypertensive medication non-adherence: a systematic review. J Hum Hypertens. 2017;31(11):687\u201394.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"4714_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3345\/cep.2021.01466","volume":"67","author":"TH Eom","year":"2024","unstructured":"Eom TH, Kim YH. Clinical practice guidelines for attention-deficit\/hyperactivity disorder: recent updates. Clin Exp Pediatr. 2024;67(1):26\u201334.","journal-title":"Clin Exp Pediatr"},{"issue":"5","key":"4714_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/HYPERTENSIONAHA.122.20810","volume":"80","author":"RE Schmieder","year":"2023","unstructured":"Schmieder RE, Wassmann S, Predel H-G, Weisser B, Blettenberg J, Gillessen A, et al. Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-Study. Hypertension. 2023;80(5):1127\u201335.","journal-title":"Hypertension"},{"key":"4714_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ijcard.2018.08.100","volume":"274","author":"F Holvast","year":"2019","unstructured":"Holvast F, Wouters H, Hek K, Schellevis F, Oude Voshaar R, van Dijk L, et al. Non-adherence to cardiovascular drugs in older patients with depression: a population-based cohort study. Int J Cardiol. 2019;274:366\u201371.","journal-title":"Int J Cardiol"},{"issue":"23","key":"4714_CR34","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.jacc.2020.04.038","volume":"75","author":"C Wang","year":"2020","unstructured":"Wang C, Yuan Y, Zheng M, Pan A, Wang M, Zhao M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol. 2020;75(23):2921\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"4714_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/npy.13.59","volume":"3","author":"JN Epstein","year":"2013","unstructured":"Epstein JN, Loren RE. Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry (London). 2013;3(5):455\u20138.","journal-title":"Neuropsychiatry (London)"},{"issue":"3","key":"4714_CR36","doi-asserted-by":"publisher","first-page":"e210321","DOI":"10.1001\/jamanetworkopen.2021.0321","volume":"4","author":"Y Shi","year":"2021","unstructured":"Shi Y, Hunter Guevara LR, Dykhoff HJ, Sangaralingham LR, Phelan S, Zaccariello MJ, et al. Racial disparities in diagnosis of attention-deficit\/hyperactivity disorder in a US national birth cohort. JAMA Netw Open. 2021;4(3):e210321.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"4714_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jaac.2018.11.016","volume":"58","author":"C Mohr-Jensen","year":"2019","unstructured":"Mohr-Jensen C, M\u00fcller Bisgaard C, Boldsen SK, Steinhausen HC. Attention-deficit\/hyperactivity disorder in childhood and adolescence and the risk of crime in young adulthood in a Danish nationwide study. J Am Acad Child Adolesc Psychiatry. 2019;58(4):443\u201352.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"4714_CR38","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/bcp.13569","volume":"84","author":"SS Ormh\u00f8j","year":"2018","unstructured":"Ormh\u00f8j SS, Potteg\u00e5rd A, Gasse C, Rasmussen L. Use of attention-deficit\/hyperactivity disorder medication among older adults in Denmark. Br J Clin Pharmacol. 2018;84(7):1505\u201313.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04714-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:20:43Z","timestamp":1771856443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04714-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4714"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04714-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the relevant authorities in each participating country: Australia (AIHW HREC EO2021\/1\/1233; NSW PHSREC 2020\/ETH02273), Denmark (Danish Data Protection Agency; Act no. 1338 of 1 September 2020), the Netherlands (Statistics Netherlands project agreement 9205), Norway (Regional Ethics Committee in Western Norway 2020\/75421), Sweden (Swedish Ethical Review Authority 2020-06540), the United Kingdom (THIN Scientific Review Committee 17THIN102), and the United States (SUNY Upstate Medical University IRB 1933232-2). Informed consent was waived in all countries due to the use of de-identified or pseudonymized registry data.Not applicable, as the study used de-identified registry data and did not involve direct patient contact.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HL reports receiving grants from TAKEDA and Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire\/Takeda Pharmaceuticals and Evolan Pharma AB; all outside the submitted work. HL is editor-in-chief of JCPP Advances. SVF reports personal fees and travel expenses from Mentavi\/ADHD Online, Axsome, Ironshore\/Collegium, KemPharm\/Corium, Noven, Supernus, Sandoz, Tris and Medice; has a US patent (via his institution) for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD (US20130217707 A1); receives royalties from books published by Guilford Press (Straight Talk about Your Child's Mental Health), Oxford University Press (Schizophrenia: The Facts), and Elsevier (ADHD: Non-Pharmacologic Interventions); and is program director of\n                      \n                      and\n                      \n                      . KKCM reports grants from the C W Maplethorpe Fellowship, the National Institute for Health and Care Research, Innovation and Technology Commission of the Hong Kong Special Administration Region Government, and Hong Kong Research Grant Council; and personal fees from IQVIA, all outside the submitted work. ICKW reports research funding from Amgen and GSK, the Hong Kong Research Grants Council, the Hong Kong Health and Medical Research Fund, the National Institute for Health Research in England, the European Commission, and the National Health and Medical Research Council in Australia, consulting fees from IQVIA and World Health Organisation, outside of the submitted work. He is a non-executive director of Jacobson Medical, Advance Data Analytics for Medical Science (ADAMS) Limited in Hong Kong and OCUS Innovation Limited (HK, Ireland and UK); a former director of Therakind in England and Asia Medicine Regulatory Affairs (AMERA) Services Limited in Hong Kong. ZC received speaker fees from Takeda Pharmaceuticals, outside the submitted work. All other authors declare no competing interests. ASCY reports grant from the University College London Hospitals NIHR Biomedical Research Centre, College of Mental Health Pharmacy, and UK Turing Scheme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}